Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker Exelixis
So what: Shareholders never like to see their stock diluted, so the negative reaction shouldn’t be surprising. The development-stage biotech hopes to sell 20-million new shares, and raise $225 million in convertible debt, because it's still unprofitable and needs to fund future research. At a market cap of just $720 million, the offering dilutes share value by more than 10%, so the drop in share price looks warranted. Over the last week, shares have fallen about 25%, as the company reported a sharp decline in quarterly earnings due to transferring development activities on certain drugs to Sanofi.
Now what: As a young biotech, this stock is essentially binary, with its outcome riding on the results of its cabozantinib drug, now entering Phase 3 testing. The drug is used to reduce tumor growth in cancers of the liver, kidney, and ovaries. Considering the potential returns if the drug is successful, today’s movement is essentially noise. Investors should keep up an eye on cabozantinib’s Phase 3 trials for a better idea of where the stock is going. Initial Phase 3 trials have shown positive results.
Need another prescription for Exelixis? Get all the news you need by adding it to your watchlist.